The House Ways and Means Committee has proposed several insurance reforms in its emergency COVID-19 relief package, including increasing subsidizes and extending subsidies to people with higher incomes. The proposed combined approach is a far more efficient means of covering uninsured Americans than enhancing subsidies only for those who are currently eligible.
Despite the buzz and catchy notion that subscription models are “Netflix for drugs,” it's hard to come up with a theoretical case that supports subscription models over traditional price negotiation between payers and manufacturers over a per-dose or per-unit price.
At a time when it has become common to think of the UK as a divided society, there are important questions of policy on which a great many people agree. How to fund the ever-growing needs of the NHS and social care is one such area of agreement.
RAND serves as an objective source of facts that help inform the world's most pressing policy debates. When decisions are based on the best evidence, that's when public policy can have a positive impact on people's lives. We're highlighting the 10 research projects that RAND.org readers found most engaging this year.
Traditional Medicare is popular and therefore can lend a good brand name to coverage expansion proposals, but its limits can be significant for some patients. Those proposing and evaluating “Medicare for All” proposals should consider whether and how these limits are addressed.
Medicare for All is a talking point for both major U.S. political parties. Would it be free? Would people have to switch doctors? Would waits be long? Misconceptions abound about single-payer proposals and their likely effects. Here are the facts.
Jodi Liu, an associate policy researcher at RAND, studies how to deliver high-quality care and how to pay for it. She discusses her assessment of a single-payer health care proposal in New York State and the supply-and-demand challenges that might arise if an Alzheimer's treatment became available.
Starting in 2019, the Affordable Care Act's individual mandate penalty will be eliminated, effectively ending the law's requirement that most people have health insurance. While declines in coverage and increases in premiums are likely, the magnitudes of these effects are highly uncertain.
A single-payer plan in New York would shift health care spending to the state instead of private insurers. As with any far-reaching legislation, there are trade-offs. It's important that policymakers consider the impact of the single-payer plan in totality.
The case for raising much more money to pay for health care and social care in the United Kingdom over the next few years is strong. Earmarking taxes for public funding of health care or social care is worth consideration.
Despite their differences, the Affordable Care Act and the current proposals to replace it take a similar approach to providing health insurance. What might some alternatives look like? And how could they provide coverage to more Americans?
Starting in 2019, the Medicare Access and CHIP Reauthorization Act will integrate and potentially simplify performance measurement by combining many measures and programs. Research provides insight into how to avoid pitfalls in MACRA's rollout.
Insurers, employers, and industry are some of the stakeholder groups that are critical to the success of comparative-effectiveness research. Current research models may not provide stakeholders with all the information they need to support their involvement.
The impact of RAND's Health Insurance Experiment has been wide-reaching. The study's conclusions encouraged the restructuring of private insurance and helped increase the stature of managed care in the United States.
Research-based pharmaceutical companies that truly innovate could distance themselves from companies that operate like hedge funds, seeking out investment opportunities rather than focusing on research.
A review in 2017 of the adequacy and use of Patient-Centered Outcomes Research Trust Funds will be used to determine whether funding levels should be continued or adjusted after its authorization runs out in 2019. Researchers ought to take stock of the work in patient-centered outcomes research.
A new approach may be needed to finance an emerging breed of expensive but highly effective pharmaceuticals and vaccines. The health care industry could learn from other industry approaches such as equipment leases or supplier-financed credit.
The Affordable Care Act has officially been part of the U.S. health care landscape for five years. We reflect on the twists and turns that followed its passage and the RAND research that informed debates along the way, and look ahead to the future of the ACA.
Depression is the leading cause of disability throughout the world and is especially prevalent among low-income African countries, where 75 percent of the people who suffer from mental illness do not have easy access to the mental health care they need.
Patient experience with care is an essential element in any assessment of health care quality. Surveys give patients a voice and provide fair and relevant indicators that complement other metrics of health care quality to inform patients' choices and providers' decisions about how to improve care.
It's not unusual for a demonstration to fall short of its original objectives. Learning from such cases is part of the innovation process. This is especially worthwhile for bundled payment, which has many potential benefits for patients, providers, and payers.
Expanding Medicaid under the Affordable Care Act (ACA) is both contentious and complicated. RAND mathematician Carter Price has been using the COMPARE model to help those making decisions understand what their choices mean for their budgets and population health.
Resolving the question of whether or not the U.S. has finally gotten a handle on health care spending is vitally important, because the choices we make going forward will have profound implications for our economy, the financial wellbeing of millions of American families, and ultimately America's standing in the world.
Given the size of the annual “health care spend”—$2.7 trillion—summing up the savings associated with very minor cost-saving policy changes is likely to achieve significant aggregate savings, writes Jeffrey Wasserman.
Unfortunately, nearly every actor in our health care delivery system—hospitals, physicians, other health care providers, insurance companies and the manufacturers of drugs and devices—is currently focused on maximizing revenue growth, write Arthur Kellermann and David Auerbach.
The Affordable Care Act focuses primarily on extending coverage to uninsured Americans, but it is also intended to help curb cost growth. M. Susan Ridgely explains one of the key tools for doing that—the “accountable care organization,” an alternative delivery model intended to lower costs while also improving quality of care.
A problem with using surveys to predict behavior is that they measure employer sentiment toward the ACA today, rather than the economic decisions employers typically make when the time comes, writes Art Kellermann.
As the U.S. Supreme Court considers the constitutionality of the Affordable Care Act's (ACA) individual mandate, one of the questions being debated is what effect the mandate would have on employer-sponsored health insurance coverage. A factor to consider in this is the effect the ACA would have on small businesses, which employ the majority of America's private-sector workforce.
Pay for performance, transparency, and other innovative ways of compensating physicians will work only if, at the same time, the system for providing care is changed to one that has clear objectives and provides specific tools to help physicians achieve those objectives, writes Robert H. Brook.
In general, health insurance premiums are set at a level that will cover the expected payouts for insured people plus profit. To provide a context for understanding price increases, this document identifies the factors that insurance companies consider when setting rates for the next year, writes Elizabeth McGlynn.
President Obama and several Congressional leaders have recently expressed support for the idea of allowing citizens to buy into a public insurance program as part of any health reform legislation. The intensity of the ensuing debate has been fascinating given the lack of specifics that have been offered by either side, writes Elizabeth A. McGlynn.